Prevalence of mutations in common tumour types in Northern England and comparable utility of national and international Trial Finders

Rae, S.; Plummer, E.; Fitzgerald, L.; Hogarth, L.; Bridgewood, A.; Brown-Schofield, L.; Graham, J.; Haigh, S.; McAnulty, C.; Drew, Y.; Haris, N.; Bashir, S.; Plummer, R.; Greystoke, A.

doi:10.1007/s00432-023-05365-y

Cited by 1 publication

(1 citation statement)

References 27 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Herein, we summarized recent clinical studies that utilized PCa organoids and model systems for evaluating the novel therapies for PCa diseases (Table 2). These studies included the clinical trials conducted at Centre Antoine Lacassagne in France (NCT03952793) [121], The Christie NHS Foundation Trust in the UK (NCT04723316) [122], the Netherlands Cancer Institute in the Netherlands (NCT02695459), Fudan University in China (NCT04927611) [123], SpeciCare, Georgia, USA (NCT03896958) [124], and the Rutgers Cancer Institute in New Jersey (NCT02458716) [36] (Table 2). Recently, a PDO-based model was employed in a Phase II trial (NCT01799278) for investigating the efficacy of the aurora kinase inhibitor Alisertib (MLN8237) for mCRPC and NEPC.…”

Section: Clinical Implications and Therapeutic Approachmentioning

confidence: 99%

Organoids: An Emerging Precision Medicine Model for Prostate Cancer Research

Waseem,

Wang

2024

IJMS

View full text Add to dashboard Cite

Prostate cancer (PCa) has been known as the most prevalent cancer disease and the second leading cause of cancer mortality in men almost all over the globe. There is an urgent need for establishment of PCa models that can recapitulate the progress of genomic landscapes and molecular alterations during development and progression of this disease. Notably, several organoid models have been developed for assessing the complex interaction between PCa and its surrounding microenvironment. In recent years, PCa organoids have been emerged as powerful in vitro 3D model systems that recapitulate the molecular features (such as genomic/epigenomic changes and tumor microenvironment) of PCa metastatic tumors. In addition, application of organoid technology in mechanistic studies (i.e., for understanding cellular/subcellular and molecular alterations) and translational medicine has been recognized as a promising approach for facilitating the development of potential biomarkers and novel therapeutic strategies. In this review, we summarize the application of PCa organoids in the high-throughput screening and establishment of relevant xenografts for developing novel therapeutics for metastatic, castration resistant, and neuroendocrine PCa. These organoid-based studies are expected to expand our knowledge from basic research to clinical applications for PCa diseases. Furthermore, we also highlight the optimization of PCa cultures and establishment of promising 3D organoid models for in vitro and in vivo investigations, ultimately facilitating mechanistic studies and development of novel clinical diagnosis/prognosis and therapies for PCa.

show abstract